IdentificationGeneric Name(2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-olDrugBank Accession NumberDB08285BackgroundNot AvailableTypeSmall MoleculeGroupsExperimentalStructure


3DDownload MOLSDF3D-SDFPDBSMILESInChI


 Similar StructuresStructure for (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol (DB08285)× CloseWeightAverage: 354.4493 Monoisotopic: 354.216809484 Chemical FormulaC19H26N6OSynonymsNot AvailablePharmacologyIndicationNot AvailableReduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, & validate predictive machine-learning models with structured datasets.See howContraindications & Blackbox WarningsAvoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Learn more  Avoid life-threatening adverse drug events & improve clinical decision support.Learn morePharmacodynamicsNot AvailableMechanism of actionTargetActionsOrganismUCyclin-dependent kinase 2Not AvailableHumansUCyclin-A2Not AvailableHumansAbsorptionNot AvailableVolume of distributionNot AvailableProtein bindingNot AvailableMetabolismNot AvailableRoute of eliminationNot AvailableHalf-lifeNot AvailableClearanceNot AvailableAdverse EffectsImprove decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Learn more  Improve decision support & research outcomes with our structured adverse effects data.Learn moreToxicityNot AvailablePathwaysNot AvailablePharmacogenomic Effects/ADRs 


Not AvailableInteractionsDrug Interactions 


This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. Not AvailableFood InteractionsNot AvailableCategoriesDrug CategoriesNot AvailableChemical TaxonomyProvided by ClassyfireDescriptionThis compound belongs to the class of organic compounds known as 2-benzylamino-s-triazines. These are aromatic heterocyclic compounds containing a S-triazine ring, which is N-substituted at the 2-position with a benzylamine.KingdomOrganic compoundsSuper ClassOrganoheterocyclic compoundsClassTriazinesSub ClassAminotriazinesDirect Parent2-benzylamino-s-triazinesAlternative ParentsPyrazolotriazines / Pyrazolo[1,5-a][1,3,5]triazines / Benzylamines / 1,3,5-triazine-2,4-diamines / Secondary alkylarylamines / 1,3,5-triazines / Pyrazoles / Heteroaromatic compounds / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives


 show 2 moreSubstituents1,3,5-triazine / 2,4-diamine-s-triazine / 2-benzylamino-s-triazine / Alcohol / Amine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Benzylamine / Heteroaromatic compound / Hydrocarbon derivative / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Primary alcohol / Pyrazole / Pyrazolo[1,5-a][1,3,5]triazine / Pyrazolotriazine / Secondary aliphatic/aromatic amine / Secondary amine


 show 14 moreMolecular FrameworkAromatic heteropolycyclic compoundsExternal DescriptorsNot AvailableAffected organismsNot AvailableChemical IdentifiersUNIINot AvailableCAS numberNot AvailableInChI KeySQUNOCMDMIQIQK-OAHLLOKOSA-NInChIInChI=1S/C19H26N6O/c1-4-15(12-26)22-18-23-17-16(13(2)3)11-21-25(17)19(24-18)20-10-14-8-6-5-7-9-14/h5-9,11,13,15,26H,4,10,12H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1IUPAC Name(2R)-2-{[4-(benzylamino)-8-(propan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-olSMILES[H][C@@](CC)(CO)NC1=NC2=C(C=NN2C(NCC2=CC=CC=C2)=N1)C(C)CReferencesGeneral ReferencesNot AvailableExternal LinksPubChem Compound25190761PubChem Substance99444756ChemSpider24700216BindingDB27217ChEMBLCHEMBL482193PDBe LigandNNNPDB Entries3dogClinical TrialsClinical Trials 


PhaseStatusPurposeConditionsCountPharmacoeconomicsManufacturersNot AvailablePackagersNot AvailableDosage FormsNot AvailablePricesNot AvailablePatentsNot AvailablePropertiesStateSolidExperimental PropertiesNot AvailablePredicted PropertiesPropertyValueSourceWater Solubility0.0132 mg/mLALOGPSlogP3.21ALOGPSlogP3.49ChemaxonlogS-4.4ALOGPSpKa (Strongest Acidic)13.32ChemaxonpKa (Strongest Basic)2.77ChemaxonPhysiological Charge0ChemaxonHydrogen Acceptor Count6ChemaxonHydrogen Donor Count3ChemaxonPolar Surface Area87.37 Å2ChemaxonRotatable Bond Count8ChemaxonRefractivity116.79 m3·mol-1ChemaxonPolarizability40.38 Å3ChemaxonNumber of Rings3ChemaxonBioavailability1ChemaxonRule of FiveYesChemaxonGhose FilterYesChemaxonVeber's RuleNoChemaxonMDDR-like RuleYesChemaxonPredicted ADMET FeaturesPropertyValueProbabilityHuman Intestinal Absorption+1.0Blood Brain Barrier+0.5268Caco-2 permeable-0.5874P-glycoprotein substrateSubstrate0.7894P-glycoprotein inhibitor INon-inhibitor0.7647P-glycoprotein inhibitor IINon-inhibitor0.8771Renal organic cation transporterNon-inhibitor0.8042CYP450 2C9 substrateNon-substrate0.8358CYP450 2D6 substrateNon-substrate0.7949CYP450 3A4 substrateNon-substrate0.571CYP450 1A2 substrateInhibitor0.8323CYP450 2C9 inhibitorInhibitor0.6138CYP450 2D6 inhibitorNon-inhibitor0.5727CYP450 2C19 inhibitorNon-inhibitor0.8761CYP450 3A4 inhibitorNon-inhibitor0.6882CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8829Ames testNon AMES toxic0.6384CarcinogenicityNon-carcinogens0.7073BiodegradationNot ready biodegradable1.0Rat acute toxicity2.6033 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.7847hERG inhibition (predictor II)Non-inhibitor0.7439  ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397) SpectraMass Spec (NIST)Not AvailableSpectraSpectrumSpectrum TypeSplash KeyPredicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot AvailableTargetsBuild, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock newinsights and accelerate drug research.Learn more  Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.Learn moreBinding Properties×PropertyMeasurementpHTemperature (°C)ReferencesIC 50 (nM)407.530A30565


 Details


 Binding Properties1. Cyclin-dependent kinase 2KindProteinOrganismHumansPharmacological actionUnknownGeneral FunctionMetal ion bindingSpecific FunctionSerine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, N...Gene NameCDK2Uniprot IDP24941Uniprot NameCyclin-dependent kinase 2Molecular Weight33929.215 DaReferencesBerman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article] 


 Details2. Cyclin-A2KindProteinOrganismHumansPharmacological actionUnknownGeneral FunctionNot AvailableSpecific FunctionEssential for the control of the cell cycle at the G1/S (start) and the G2/M (mitosis) transitions.Gene NameCCNA2Uniprot IDP20248Uniprot NameCyclin-A2Molecular Weight48550.365 DaReferencesBerman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article] ×Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   Drug created at September 15, 2010 21:30 / Updated at June 12, 2020 16:52 